{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Huffman BM"],"funding":["Stand Up To Cancer","Breakthrough Cancer","National Cancer Institute","Lustgarten Foundation","NCI NIH HHS","Hale Family Center for Pancreatic Cancer Research"],"pagination":["5047-5056"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10842136"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["29(24)"],"pubmed_abstract":["<h4>Purpose</h4>Combining gemcitabine with CHK1 inhibition has shown promise in preclinical models of pancreatic ductal adenocarcinoma (PDAC). Here, we report the findings from a phase I expansion cohort study (NCT02632448) investigating low-dose gemcitabine combined with the CHK1 inhibitor LY2880070 in patients with previously treated advanced PDAC.<h4>Patients and methods</h4>Patients with metastatic PDAC were treated with gemcitabine intravenously at 100 mg/m2 on days 1, 8, and 15, and LY2880070 50 mg orally twice daily on days 2-6, 9-13, and 16-20 of each 21-day cycle. Pretreatment tumor biopsies were obtained from each patient for correlative studies and generation of organoid cultures for drug sensitivity testing and biomarker analyses.<h4>Results</h4>Eleven patients with PDAC were e"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma."],"pmcid":["PMC10842136"],"funding_grant_id":["P30 CA006516","P50CA127003","P50 CA127003"],"pubmed_authors":["Sadatrezaei G","Dunwell S","Andrews E","Wang J","Getchell Z","Raghavan S","Perez KJ","Shapiro GI","Singh H","Huffman BM","Kapner KS","Rubinson DA","Schlechter BL","Aguirre AJ","Ng K","Hannigan AM","Abrams TA","Giannakis M","Fortier C","Kochupurakkal B","Patel AK","D'Andrea AD","Wolpin BM","Feng H","Cleary JM","Parmar K","Biller LH","Martignetti DB"],"additional_accession":[]},"is_claimable":false,"name":"A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.","description":"<h4>Purpose</h4>Combining gemcitabine with CHK1 inhibition has shown promise in preclinical models of pancreatic ductal adenocarcinoma (PDAC). Here, we report the findings from a phase I expansion cohort study (NCT02632448) investigating low-dose gemcitabine combined with the CHK1 inhibitor LY2880070 in patients with previously treated advanced PDAC.<h4>Patients and methods</h4>Patients with metastatic PDAC were treated with gemcitabine intravenously at 100 mg/m2 on days 1, 8, and 15, and LY2880070 50 mg orally twice daily on days 2-6, 9-13, and 16-20 of each 21-day cycle. Pretreatment tumor biopsies were obtained from each patient for correlative studies and generation of organoid cultures for drug sensitivity testing and biomarker analyses.<h4>Results</h4>Eleven patients with PDAC were e","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2026-05-29T17:08:32.341Z","creation":"2026-04-08T05:27:55.968Z"},"accession":"S-EPMC10842136","cross_references":{"pubmed":["37819936"],"doi":["10.1158/1078-0432.CCR-23-2005","10.1158/1078-0432.ccr-23-2005"]}}